Last updated: 02/04/2020 15:10:06
Treatment retention rate of paroxetine CR in the naturalistic setting (A pilot investigation)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Treatment retention rate of paroxetine CR in the naturalistic setting (A pilot investigation)
Trial description: The objective of this pilot investigation is to assess the treatment retention rate of paroxetine CR.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Time to discontinuation
Timeframe: within the first 2 months after the date of the first prescription
Secondary outcomes:
Percentage of patients remaining on therapy on each day from Day 1 to Month 2 of treatment among patients who started treatment
Timeframe: within the first 2 months after the date of the first prescription
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2013-31-10
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
Toshifumi Kimura, Hirofumi Hashimoto.Treatment Persistence with Antidepressants in Japan: Assessment of the First 60 Days of Treatment Based on Pharmacy Claims Data from Reimbursement Database.Ther Res.2015;36(6):571-580
Medical condition
Depressive Disorder, Major
Product
amitriptyline, amoxapine, clomipramine, dosulepin, duloxetine, escitalopram, fluvoxamine, imipramine, lofepramine, maprotiline, mianserin, milnacipran, mirtazapine, nortriptyline, paroxetine, sertraline, setiptiline, trazodone, trimipramine
Collaborators
Not applicable
Study date(s)
April 2013 to October 2013
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
none
- At least 20 years of age and presence of prescription of an antidepressant between June 2012 and December 2012
- No prescription (period) of an antidepressant within 6 months before the start of treatment
- Presence of prescription (period) of an antipsychotic drug (N05A) within 6 months before the start of treatment
- Presence of prescription (period) of a mood-stabilizing drug (Li, valproic acid, carbamazepine, or lamotrigine) within 6 months before the start of treatment
Inclusion and exclusion criteria
Inclusion criteria:
- At least 20 years of age and presence of prescription of an antidepressant between June 2012 and December 2012
- No prescription (period) of an antidepressant within 6 months before the start of treatment
- The antidepressant given as monotherapy
Exclusion criteria:
- Presence of prescription (period) of an antipsychotic drug (N05A) within 6 months before the start of treatment -Presence of prescription (period) of a mood-stabilizing drug (Li, valproic acid, carbamazepine, or lamotrigine) within 6 months before the start of treatment
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2013-31-10
Actual study completion date
2013-31-10
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website